Disabilities
Also known as: Disability, Disabled, Impairment
Methodology & AI Transparency ⓘ
Disabilities Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What are disabilities? A disability is any condition of your body or mind that makes it more difficult for you to do one or more major life activities and interact with the world around you.
- 2 Real-world patient consensus: Synonyms for Disabilities (Z78.9): Disability, Disabled, Impairment (Weight & Metabolism).
- 3 Typical cash cost range: Clinicians assessing Disabilities focus on ectopic hepatic lipid in Disabilities (Z78.9: storage) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Disabilities: maintaining Waist-to-Height Ratio [Disabilities Z78.9] within < 0.50 (Z78.9).
Ask our AI Specialists anything about Disabilities
What Is Disabilities?
What are disabilities? A disability is any condition of your body or mind that makes it more difficult for you to do one or more major life activities and interact with the world around you. There are many types of disabilities, such as those that can affect your: Vision Hearing Movement Thinking Remembering Learning Communicating Development Mental health Social relationships More than 1 in 4 adults in the United States have some type of disability. Even though they all have disabilities, they can have a wide range of needs. For example, even people who have same type of disability can be affected in very different ways.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Disabilities (Z78.9) features ectopic hepatic lipid in Disabilities (Z78.9: storage). Cross-referenced with NIH MeSH (Health Services for Persons with Disabilities, Persons with Disabilities), therapeutic stabilization in weight & metabolism is verified against HOMA-IR Insulin Resistance in Disabilities (Z78.9: Index).
Common Symptoms & Clinical Signs
- • Social relationships
- • Disorders in single genes , such as Duchenne muscular dystrophy
- • Presentation of Disabilities (Z78.9): joint load discomfort in Disabilities (Z78.9: in knees, hips,)
- • Secondary Disabilities clinical sign: daytime sluggishness or in Disabilities (Z78.9: loud snoring linked)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Disabilities Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Z78.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Waist-to-Height Ratio [Disabilities Z78.9] | < 0.50 (Z78.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in Disabilities (Z78.9: Index) | < 1.4 (Z78.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT & Fasting in Disabilities (Z78.9: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (Z78.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Disabilities
Treatment selection for Disabilities depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Disabilities)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Tirzepatide as a novel effective and safe strategy for treating: What a 11,758-Participant Study Found Tirzepatide, as a weight loss drug, significantly reduces BMI, waist circumference and body weight while gastrointestinal adverse reactions need to be vigilant. Frontiers in public health • 2024-01-15 • Meta-Analysis | N = 11,758 | 99/100 | PMID 38356942 ↗ |
| New Insights on Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and: What a 14,059-Participant Study Found Tirzepatide, particularly at higher doses, provides the greatest weight reduction in adults without diabetes. Obesity (Silver Spring, Md.) • 2026-06-15 • Meta-Analysis | N = 14,059 | 99/100 | PMID 41936548 ↗ |
| New Insights on Empagliflozin in combination with oral agents in young and overweight/obese type: What a 439-Participant Study Found In this specific population, empagliflozin in combination with other oral agents, significantly reduced HbA1c and body weight and was well tolerated. Journal of diabetes and its complications • 2016-01-15 • Phase III Randomized Trial | N = 439 | 93/100 | PMID 27499456 ↗ |
| New Insights on Statins for primary prevention of heart and blood vessel disease and persistent: What a 5,981-Participant Study Found There were minimal differences in CVD outcomes and no significant difference in persistent physical disability between various forms of statins in healthy older adults. European journal of clinical pharmacology • 2022-03-15 • Randomized Controlled Trial | N = 5,981 | 90/100 | PMID 34698889 ↗ |
| Can This Approach Help? Inside the Latest Research on PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Treatment with PDE5i in humans and murine models of diabetes improves VAT, targeting SIRT1 through a modulation of miR-22-3p expression. The Journal of clinical endocrinology and metabolism • 2016-04-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 26964730 ↗ |
Disabilities Patient Community & “People Like Me” Threads
Filter Disabilities community threads and patient logs by age, biological sex, dosage, and treatment duration.